HCA HCA Healthcare, Inc.
Services-General Medical & Surgical Hospitals, NEC · NYSE · SEC CIK 860730 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY6.8%
TTM EPS YoY16.6%
Revenue 3-yr CAGR7.6%
Net income 3-yr CAGR5.8%
Margins
Gross margin—
Operating margin—
Net margin8.6%
FCF margin7.6%
EBITDA margin—
Returns
ROE—
ROA11.0%
ROIC (approx.)—
Asset turnover1.28x
Leverage & solvency
Liabilities / assets107.2%
Debt / equity—
Current ratio0.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.65x
Accruals ratio-7.1%
Payout ratio10.1%
Capex / revenue6.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $75.60B | $70.60B |
| SG&A expense | $548.00M | $421.00M |
| Interest expense | $2.25B | $2.06B |
| Pretax income | $9.83B | $8.52B |
| Income tax | $2.05B | $1.87B |
| Net income | $6.78B | $5.76B |
| EPS (basic) | 28.70 | 22.27 |
| EPS (diluted) | 28.33 | 22.00 |
| Dividends declared per share | 2.88 | 2.64 |
| Weighted avg. shares (diluted) | 239.50M | 261.81M |
| Balance sheet | ||
| Cash & equivalents | $1.04B | $1.93B |
| Receivables | $10.87B | $10.75B |
| Inventory | $1.65B | $1.74B |
| Current assets | $15.78B | $16.41B |
| PP&E, net | $31.14B | $29.41B |
| Total assets | $60.72B | $59.51B |
| Current liabilities | $16.35B | $15.18B |
| Short-term debt | $4.89B | $4.70B |
| Long-term debt | $41.60B | $38.33B |
| Total debt | $46.49B | $43.03B |
| Total liabilities | $63.49B | $58.96B |
| Shareholders' equity | -$6.03B | -$2.50B |
| Net debt | $45.45B | $41.10B |
| Shares outstanding | 224.61M | 249.98M |
| Cash flow statement | ||
| Operating cash flow | $12.64B | $10.51B |
| Capital expenditure | $4.94B | $4.88B |
| Free cash flow | $7.69B | $5.64B |
| Investing cash flow | -$4.99B | -$4.93B |
| Financing cash flow | -$8.55B | -$4.58B |
| Depreciation & amortization | $3.52B | $3.31B |
| Stock-based compensation | $401.00M | $360.00M |
| Dividends paid | $679.00M | $690.00M |
| Share buybacks | $10.07B | $6.04B |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.